Persistent pulmonary hypertension of the newborn (PPHN) occurs when the pulmonary vascular resistance remains elevated after birth, resulting in right to left shunting of blood through fetal circulatory pathways. This, in turn, leads to severe hypoxemia that may not respond to conventional respiratory support. The prevalence of PPHN has been estimated at 1.9 per 1000 live births[@b1]. PPHN can be easily triggered in newborns by hypoxic lung diseases such as meconium aspiration syndrome, respiratory distress syndrome, and pneumonia.

Recent studies of pulmonary hypertension in adults and neonates have increased our understanding of the genetic basis of the disease. On one hand, genes involved in the transforming growth factor-β superfamily, nitric oxide pathway, potassium channel family and endothelin system have been implicated in pulmonary arterial hypertension and/or PPHN[@b2][@b3][@b4]. On the other hand, vasoactive substances, including nitric oxide (NO), endothelin-1 (ET-1), angiotensin-II (ANG-II) and vascular endothelial growth factor (VEGF), contribute to progressive changes to pulmonary vasoreactivity via the related genes *NOS3, EDN1, ACE* and *VEGFA*[@b5][@b6][@b7][@b8]. Endothelial nitric oxide synthase is encoded by *NOS3*[@b9]. Variants of this gene have been reported to be associated with coronary spasm and hypertension. ET-1 is one of the most potent and long-lasting vasoconstrictors encoded by *EDN1*. It plays an important role in pulmonary arterial hypertension[@b10]: increased levels of ET-1 were detected in patients with some forms of pulmonary arterial hypertension[@b11]. The association of *EDN1* gene polymorphisms with hypertension and pulmonary arterial hypertension has been described[@b12][@b13]. Angiotensin-converting enzyme (ACE) is a key enzyme in the renin-angiotensin system (RAS) and is for the conversion of ANG-I to ANG-II in the circulation, thereby playing a crucial role in blood pressure regulation[@b14]. It has been suggested that *ACE* gene polymorphisms determine the phenotypic variations of enzyme levels and are associated with essential hypertension[@b15][@b16][@b17]. *VEGFA* encodes VEGF, a potent endothelial mitogen with angiogenic and vasoactive properties that plays a critical role in lung development[@b18]. Therefore, the aim of this study was to evaluate the association of *NOS3, EDN1, ACE* and *VEGFA* genes and PPHN.

Materials and Methods
=====================

This study was approved by the ethics committee of the Children's Hospital of Fudan University and performed from January 2013 to January 2014. The methods were carried out in accordance with the approved guidelines.

Patients
--------

The population of this study consisted of infants (gestational age ≥34 weeks and birth weight ≥2000 g) who were admitted to the neonatal intensive care unit within 3 days of birth with clinical evidence of respiratory distress.

The inclusion criteria were: Neonates who were born at 34 weeks' gestation or later, weighed at least 2000g at birth, aged within 3 days, and were admitted to Children's Hospital of Fudan University with hypoxemic respiratory failure and a requirement for supplemental assisted mechanical ventilation.

The exclusion criteria were: Neonates with structural congenital heart disease excluding patent ductus arteriosus or patent foramen ovale, congenital anomalies such as congenital diaphragmatic hernia.

According to the previous study[@b3], PPHN was diagnosed by clinical and echocardiographic data. Clinical criteria consisted of sustained partial pressures of arterial oxygen below 100 mmHg while breathing 100 percent supplemental oxygen, despite mechanical ventilation. Echocardiographic criteria included a structurally normal heart and an elevated pulmonary arterial pressure, that was considered present if there was either right-to-left or bidirectional flow across the patent ductus arteriosus or foramen ovale or a systolic pulmonary arterial pressure greater than or equal to the systemic blood pressure according to Doppler measurement of the tricuspid-regurgitation jet. Infants with respiratory distress who did not have pulmonary hypertension according to these criteria were designated as non-PPHN.

After informed consent was obtained from a parent, infants met above mentioned criteria were divided into two groups: PPHN group and non-PPHN group. Blood sample collection was completed before inhaled nitric oxide administration.

Candidate gene sequencing by next-generation sequencing (NGS)
-------------------------------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA Mini Kit (Qiagen, Germany). The DNA concentration was measured using a NanoDrop spectrophotometer (ND-1000, Thermo Fisher Scientific, USA). Genomic DNA samples were tested by NGS sequencing using a custom-designed panel based on an AmpliSeq strategy. The panel, created using the Ion AmpliSeq^TM^ designer software, was designed to identify disease mutations in the following genes: *EDN1, ACE, VEGFA* and *NOS3*. This design allowed for the analysis of 70 exons (*EDN1*: 5, *ACE*: 26, *VEGFA*: 9, *NOS3*: 30) (padding: + /−50 bp). The library was prepared by following the instructions provided by the manufacturers of the kits for fragmentation (Ion Shear, Life Technologies, USA), adaptor and barcode ligation (Ion Xpres Barcode Adapters Kit, Life Technologies, USA) and library quantification (Ion Library Quantification Kit, Life Technologies, USA). We used the Ion OneTouch™ system (Life Technologies, USA) to clonally amplify pooled, barcoded libraries on Ion Sphere™ particles. Torrent Suite™ software was used to compare base calls. NextGENeTM software was used to read alignments and to call variants using the human genomic reference hg19 (NCBI). The variants selected for further analysis met the following criteria: 1) the variant was detected in the sequence reads for both strands, 2) a minimum coverage of 10× was achieved, 3) the variant reads represented \>20% of the sequence reads at a particular site, and 4) the targeted region covered all exons and at least 50 bp of all intron/splice sites. The filtered variants were then compared using dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>).

Sanger sequencing
-----------------

The variants were validated by Sanger sequencing using an automated sequencer (3500XL Genetic Analyzer, Applied Biosystems, USA).

Serum ET-1 concentration detection
----------------------------------

Serum ET-1 levels were measured using an enzyme-linked immunosorbent assay (Endothelin-1 Quantikine ELISA kit, R&D Systems, USA). Each blood sample was collected within 3 days after birth, was placed in a blank tube for 30 minutes, and was then centrifuged at 3000× g for 15 minutes. The serum was stored at −80 °C. Each step was performed according to the manufacturer's instructions.

Statistical analysis
--------------------

### Sample Size and Power Calculations

We used Quanto 1.4 version (University of Southern California) to calculate the study sample size. Research is an unmatched case-control design study. According to the references, we hypothesized that 40\~50% of patients would have a T allele in the baseline, chose inheritance model as Additive (GG, GT, TT) and estimated gene-environment model which would be no interaction between the PPHN and non-PPHN groups. Using a 2-sided α level of 0.05 and preinstalling 0.9976 power for gene to test the futility hypothesis in the analysis, a sample size of 55 patients in the PPHN group and 57 patients in the control group were included finally.

### Data analysis

Statistical analysis was performed using Stata version 12.0 for Windows (StataCorp). Baseline characteristics were compared between the PPHN and non-PPHN infants using the chi-square test for categorical variables and a Mann-Whitney-Wilcoxon or Kruskal-Wallis rank sumtest for continuous variables. Categorical variables were summarized using frequency and rate, mean and standard deviation for continuous variables. Logistic regression analyses using an α level of 0.05 were performed to determine whether gene expression increased the risk of disease occurrence. The regression imputation was based on a logistic regression model with baseline covariates for gender, gestational age, birth weight, postnatal age, maternal history of disease, and delivery mode.

Results
=======

Baseline characteristics of the enrolled infants
------------------------------------------------

In total, 112 infants were enrolled, including 55 neonates in the PPHN group and 57 neonates in the non-PPHN group. There were no significant differences in the baseline characteristics between the PPHN and non-PPHN group ([Table 1](#t1){ref-type="table"}). Among the infants in the PPHN group, the primary diagnosis were hyaline membrane disease, transient tachypnea of the newborn, perinatal asphyxia, meconium aspiration syndrome, and pneumothorax. Among the infants in the non-PPHN group, the primary diagnose were hyaline membrane disease, transient tachypnea of the newborn, perinatal asphyxia, meconium aspiration syndrome, pneumothorax and pneumonia. There was no significant difference in the primary diagnosis between the PPHN and non-PPHN group (*P* = 0.173) ([Table 1](#t1){ref-type="table"}). The maximal oxygenation-index values of the PPHN group were higher than non-PPHN group (22.335 ± 23.803 vs 6.961 ± 4.078, *P* = 0). Twenty-five (45.5%) required treatment with inhaled nitric oxide, 28 (50.9%) required vasoactive agents therapy, finally, 5 died of multiorgan failure (9.1%) in PPHN group. While only 1 (1.75%) required vasoactive agents therapy, and none required treatment with inhaled nitric oxide, 1 (1.75%) died finally in non-PPHN group.

Although pulmonary artery pressure can be measured directly by Swan Ganz Catheter. There are a number of echocardiographic indicators that help indirectly to measure pulmonary artery pressure (PAP), here we use velocity of the tricuspid regurgitation (TR) jet to assess PAP. The maximum PAP trajectories of each individual patient in PPHN group are visualized in [Fig. 1](#f1){ref-type="fig"}.

Variants in candidate gene
--------------------------

All the enrolled neonates were evaluated by NGS on the Ion Torrent Personal Genome Machine platform. Although no pathogenic mutations were identified, 48 SNPs were found ([Table 2](#t2){ref-type="table"}). Thirteen SNPs were found to significantly deviate from Hardy-Weinberg equilibrium in non-PPHN and were therefore excluded for the further analysis. An interesting observation was that differences in the distribution of allele and genotype frequencies of rs2070699 in *EDN1* were observed. A higher frequency of the rs2070699 T allele was observed in the PPHN group (OR = 3.89, 95% confidence interval (CI) 1.96--7.72, *P* = 0) ([Table 3](#t3){ref-type="table"}). After adjustment for gender, gestational age, birth weight, postnatal age, maternal history of disease, and delivery mode, logistic regression analysis showed that rs2070699 T allele carriers were more likely to be PPHN than G carriers ([Table 4](#t4){ref-type="table"}). In order to understand the association of this genetic variation and severity of the disease, serum ET-1 levels were measured in 40 patients (n = 15 in PPHN group, n = 25 in non-PPHN group).

ET-1 concentration
------------------

In the cohort of neonates tested for ET-1, there were no significant differences in the baseline characteristics between the sequenced PPHN and non-PPHN infants; ET-1 levels were 2.794 ± 2.634 pg/mL and 2.202 ± 1.731 pg/mL, respectively (*P* = 0.722). The *EDN1* GG genotype was associated with significantly lower ET-1 levels (*P* = 0.002) compared with the GT/TT genotypes. Neonates with the T allele seemed to have higher oxygenation index and longer ventilation time ([Table 5](#t5){ref-type="table"}).

Discussion
==========

At birth, the fetal cardiopulmonary system rapidly establishes the lung as the gas exchange organ by decreasing pulmonary vascular resistance and increasing pulmonary blood flow. Pulmonary hypertension can be easily triggered in newborns by hypoxic lung disease, apnea, or other causes. Interestingly, not all neonates requiring intensive care for respiratory failure develop PPHN[@b1]. The disease is most likely a manifestation of pulmonary vascular maladaptation precipitated by an interaction of environmental and genetic factors. A recent single-center study reported the results of the genotype analysis of 88 neonates with documented PPHN; no differences were noted in most candidate genes, including *BMPR2* and nitric oxide synthase[@b19]. However, PPHN was significantly associated with genetic variants of corticotropin releasing hormone receptor-1 (*CRHR1*) and CRH-binding protein, as well as with significantly increased 17-hydroxyprogesterone levels.

ET was originally isolated in 1988 from the supernatant of a porcine aortic endothelial cell culture and was demonstrated to be a strong vasoconstrictive peptide[@b20]. ET has 3 isoforms (ET-1, ET-2, and ET-3) that are translated from 3 independent genes[@b21]. Although structurally and functionally similar, the expression patterns of the 3 endothelins vary considerably. ET-1 is expressed in several tissues, including endothelial cells and cardiomyocytes, whereas ET-2 and ET-3 are mainly expressed in the gastrointestinal tract and neuronal cells, respectively[@b22]. ET-1 plays a role in a variety of vascular diseases such as hypertension, arteriosclerosis, and ischemic heart disease. ET-1 levels have been examined as an important risk factor for pulmonary arterial hypertension because plasma ET-1 levels were found to be higher in patients with pulmonary arterial hypertension[@b23]. DNA sequence variations in the *EDN1* gene locus have been reported to be associated with blood pressure levels and idiopathic pulmonary arterial hypertension[@b13][@b24][@b25].

The major objective of the present study was to investigate the association of variations of genes involved in the vasomotor reaction with the development of PPHN in patients with respiratory distress. The major findings of this study were that the rs2070699 SNP in the *EDN1* is associated with a predisposition for PPHN in neonates with respiratory distress. The T allele of rs2070699 SNP may increase the risk of PPHN under respiratory distress.

In a study investigating the susceptibility to high-altitude pulmonary edema, Charu *et al*.[@b26] found that the T allele of the rs2070699 SNP was overrepresented in subjects experiencing pulmonary edema. Rankinen *et al*.[@b12] showed that the hypertension risk associated with rs5370 was particularly enhanced by an rs2070699 polymorphism. We found that the T allele at rs2070699 was significantly associated with an increased risk of PPHN, higher plasma levels of ET-1 and a longer ventilation time under respiratory distress. We did not find that the genetic variants of *VEGFA, NOS3* and *ACE* significantly contributed to PPHN.

In conclusion, this study provides the first evidence of an association between the *EDN1* rs2070699 SNP and the risk of PPHN in Chinese neonates with respiratory distress. However, the sample size is small; thus, the result requires confirmation in a larger sample. The role of this genetic variant in the pathogenesis of PPHN should be further investigated by functional research to provide a new theoretical basis for disease control and prevention.
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###### Baseline characteristics of the enrolled infants.

                                         PPHN (N = 55)    non-PPHN (N = 57)   z/χ^2^    *P*
  ------------------------------------ ----------------- ------------------- -------- -------
  Male sex (%)                             31(56.36)          36(63.16)       0.538    0.463
  Gestational age (wk)                   37.58 ± 2.06       37.18 ± 2.05      1.197    0.232
  Birth weight (g)                      2986.1 ± 564.3     2880.6 ± 559.9     1.304    0.192
  Age at enrollment (d)                    2.4 ± 1.4          2.1 ± 0.9       0.782    0.434
  Cesarean section delivery (%)            40(74.07)          42(73.68)       0.002    0.963
  Ventilation time (d)\*                   5.4 ± 3.2          4.3 ± 3.9       3.333    0.001
  Maximal oxygenation index\*           22.335 ± 23.803     6.961 ± 4.078     6.169      0
  Inhaled nitric oxide (%)\*^Ψ^            25(45.5)               0           33.354     0
  Vasoactive agents therapy (%)\*^Ψ^      528(50.91)           1(1.75)        35.246     0
  Mortality (%)^Ψ^                          5(9.1)            1(1.75))        2.971    0.110
  **Primary diagnosis**\*^Ψ^                                                          
  Hyaline membrane disease                    28                 22           7.761    0.173
  Transient tachypnea of the newborn          13                 21                   
  Perinatal asphyxia                           9                  8                   
  Meconium aspiration syndrome                 4                  1                   
  Pneumothorax                                 1                  2                   
  Pneumonia                                    0                  3                   

\**P* \< 0.05 for the comparison between groups. ^Ψ^χ2-Fisher's Exact test.

###### SNPs identified in 112 infants by Ion Torrent sequencing.

  Gene       Chr   Nucleotide position    SNP (rs)     Nucleotide change   Minor allele frequency
  --------- ----- --------------------- ------------- ------------------- ------------------------
  *ACE*      17         61554632         rs147912715          G/A                  0.0028
             17         61556298           rs4295             C/G                  0.3666
             17         61556342         rs182340837          A/C                  0.0022
             17         61556410         rs13306087           G/A                  0.0022
             17         61556429         rs117134739          A/G                  0.0034
             17         61557200           rs4298             C/T                  0.1444
             17         61557861         rs148882466          C/T                  0.0004
             17         61559923           rs4309             C/T                  0.4235
             17         61560501         rs28730839           C/G                  0.0004
             17         61560763           rs4311             T/C                  0.3343
             17         61562309           rs4316             C/T                  0.4808
             17         61562553           rs4320             G/A                  0.4748
             17         61562774           rs4321             T/C                  0.4702
             17         61564052           rs4331             A/G                  0.4704
             17         61565990           rs4341             G/C                   0.47
             17         61565998           rs4342             A/C                   0.47
             17         61566031           rs4343             G/A                  0.3568
             17         61573761           rs4362             T/C                  0.4125
             17         61574443         rs117135474          C/T                  0.0046
             17         61574492           rs4363             G/A                  0.4181
  *EDN1*      6         12290732         rs10478694           A/-                  0.2015
              6         12292599         rs150035515          G/A                  0.0026
              6         12292615         rs183694577          G/A                  0.003
              6         12292772          rs2070699           G/T                  0.3562
              6         12294137          rs1800543           T/C                  0.274
              6         12294258           rs5369             A/G                  0.0986
              6         12296255           rs5370             G/T                  0.2474
              6         12297028          rs9296344           T/C                  0.1442
  *NOS3*      7         150696008         rs1007311           A/G                  0.4591
              7         150692444         rs1800781           G/A                  0.1084
              7         150695726         rs1549758           T/C                  0.1823
              7         150696111         rs1799983           T/G                  0.1763
              7         150698879         rs1800780           A/G                  0.4305
              7         150699250         rs1800782           G/T                  0.127
              7         150704250         rs2566514           C/G                  0.4313
              7         150704400         rs3730305           C/A                  0.1396
              7         150706383         rs753482            C/A                  0.1857
              7         150706915         rs743506            G/A                  0.2831
              7         150708089         rs891512            A/G                  0.1116
  *VEGFA*     6         43738350          rs2010963           C/G                  0.3261
              6         43738977           rs25648            C/T                  0.1212
              6         43746169          rs3025000           C/T                  0.2354
              6         43748545         rs185218985          G/A                  0.0008
              6         43748643          rs3025052           T/C                  0.011
              6         43752536          rs3025039           C/T                  0.1336
              6         43753051          rs3025040           C/T                  0.1512
              6         43753212           rs10434            A/G                  0.3476
              6         43753325          rs3025053           G/A                  0.0871

###### Genotype and allele distribution of rs2070699 in 112 neonates.

                                      PPHN     non-PPHN    χ^2^     *P*     OR      95% CI
  -------------------------------- ---------- ---------- -------- ------- ------ -------------
  Genotype frequency                                                             
   GG                               12(21.8)   30(52.6)   11.339   0.001   0.25   0.11, 0.57
   GT                               26(47.3)   23(40.4)   0.545    0.460   1.33   0.63, 2.80
   TT[Ψ](#t3-fn1){ref-type="fn"}    17(30.9)    4(7.0)    10.488   0.001   5.93   1.85, 19.03
  Allele frequency                                                               
   G                                50(45.5)   83(72.8)                                 
   T                                60(54.5)   31(27.2)   31.797     0     3.89   1.96, 7.72

\*The Chi-square test was used. Odds ratios and 95% CI were estimated using an additive model. As to *END1* gene, the T allele of rs2070699 was more prevalent in PPHN patients compared to control subjects after Bonferroni-Dunn's multiple comparisons post-hoc analysis for test groups (0.05/3), there revealed significant differences in frequencies of G/T alleles. CI: confidence interval.

^Ψ^χ2-Fisher's Exact test.

###### Logistic regression analysis of risk factors associated with PPHN Risk factor.

  Factor                       β-value   Odds Ratio    95% CI      z      *P*   
  --------------------------- --------- ------------ ---------- ------- ------- -------
  rs2070699 T allele            1.358      3.889        1.96     7.72    3.88      0
  Gestational age               0.140      1.150        0.85     1.56    0.91    0.365
  Birth weight                 −0.000      0.999        0.99     1.00    −0.29   0.769
  Gender                        0.658      1.931        0.75     5.00    1.35    0.175
  Postnatal age                 0.272      1.312        0.87     1.98    1.29    0.195
  Maternal history              0.072      1.074        0.26     4.36     0.1    0.92
  Cesarean section delivery    −0.316      0.728        0.24     2.18    −0.57   0.571
  Constant                     −7.439      0.000      3.36E-08   10.28   −1.49   0.136

R^2^ = 0.1737, *P* = 0.0013.

###### Comparison of the ET-1 levels between the different genotypes.

                                GG (N = 15)    GT + TT (N = 25)   z/χ^2^    *P*
  --------------------------- --------------- ------------------ -------- -------
  ET-1 (pg/ml)                 1.223 ± 0.856    3.333 ± 2.517     3.102    0.002
  Maximal oxygenation index    6.275 ± 3.587   20.925 ± 23.139    2.900    0.004
  Ventilation time (d)           3.6 ± 3.3        5.8 ± 2.6       3.749      0
  Mortality (%)                      0              3(12)         1.946    0.279

Note: As we believe that T allele carriers were more susceptible to PPHN, infants with the GT and TT genotypes were combined into one group.

[^1]: These authors contributed equally to this work.
